GV20 Therapeutics
Shanghai
About GV20 Therapeutics
GV20 Therapeutics is a cancer immunology drug discovery and development company that uses high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets and discover and develop effective antibody drugs. The proprietary antibody drug discovery engine developed by GV20 Therapeutics contributes to the development of a strong portfolio of immuno-oncology antibody drug candidates against novel and difficult targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.9M
- Last round: Corporate Round (Nov 2025)
- Website: bioxbh.com
- Phone: [email protected]
Industries & Categories
Big Data, Health Care
Social Profiles
Canonical: https://fsome.com/organization/gv20-therapeutics-58508 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.